Risk of Recurrence in Patients with Neuroendocrine Tumors After R0-Resection Abstract #711

Introduction: Operative treatment with curative intention is still the corner stone of all recommendations. Risk of recurrence and time frame for follow-up is not well-defined.
Aim(s): To analyse parameters influencing risk and time of recurrence after R0 resection.
Materials and methods: The data of 192 patients after R0 resection were evaluated retrospectively in regard to age, gender, functionality, primary tumor, stage, grade, immunohistological (lymph-)angioinvasion (L1; V1). Parameters significant in univariate analysis (p<0.05) were analyzed using multivariate Cox regression analysis. Median recurrence free and overall survival time were estimated with the Kaplan-Meier method.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Anja Rinke
Keywords: NEN, recurrence, grade, stage

To read results and conclusion, please login ...

Further abstracts you may be interested in

#3080 Impact of Multimodal Perioperative Treatment in Patients with Resected Non-Metastatic Grade 3 Neuroendocrine Neoplasms (NEN G3)
Introduction: Patients with grade 3 neuroendocrine neoplasm (NEN G3) have a limited prognosis. Even in a non-metastatic stage, the risk of recurrence after surgery is high. Multimodal perioperative treatment, including chemotherapy and/or radiotherapy in an adjuvant or neoadjuvant setting, has improved the prognosis in numerous tumor entities; however, it has not been systematically evaluated in NEN G3 so far. Nevertheless, perioperative chemotherapy is generally recommended in most current treatment guidelines for NEN G3.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr. med. Leonidas Apostolidis
#1114 CT Evaluation of Gastric Neuroendocrine Neoplasm Based on WHO 2010 Classification
Introduction: The 2010 WHO classification classifies GEP-NEN into grade 1, 2 and 3.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Ying Li
Authors: Li Y, Li Z W, Tang L, Cao K, ...
#1474 Curative Resection in Digestive Neuroendocrine Neoplasms: Recurrence-free Survival Rate and Definition of a Risk Score for Recurrence
Introduction: Surgery with radical intent is the only curative option for digestive neuroendocrine neoplasms (DNENs), but clinical practice shows disease-free pts recurring even after years
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Surgical treatment
Presenting Author: MD, PhD Elettra Merola
#1010 Soluble VCAM-1 and Its Relation to Clinical Staging and Histological Grading in Neuroendocrine Neoplasms (NENs)
Introduction: Cellular adhesion molecules play an important role in tumor progression and metastasis.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: MD PhD Violetta Rosiek
#2961 Our Experience Using a New Scoring System to Detect Disease Recurrence after Curative Surgical Resection of Well-Differentiated Pancreatic Neuroendocrine Tumors
Introduction: For patients with nonfunctioning pNET  ≥20 mm in size without distant metastasis, complete surgical resection is recommended as the primary curative strategy. Effective follow‐up programs are designed to detect recurrence at an early stage, given that treatment of limited disease has the most favorable outcome. However, data on post‐curative surgical recurrence remains limited, making it challenging to determine the best follow‐up strategy and to detect the best treatment options as an adjuvant therapy for selected patients.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Laura Mastrangelo